Best response to treatment for all patients and responses achieved after 4 and 8 cycles of RVDD therapy
| Response . | Best response to treatment, n (%) . | Responses after 4 and 8 cycles, n (%) . | ||
|---|---|---|---|---|
| All (N = 72) . | At MTD (n = 39) . | At 4 cycles (n = 70) . | At 8 cycles (n = 20)* . | |
| CR + nCR | 28 (39) | 13 (33) | 20 (29) | 7 (35) |
| CR | 21 (29) | 11 (28) | 14 (20) | 5 (25) |
| sCR | 11 (15) | 5 (13) | 1 (1) | 3 (15) |
| nCR | 7 (10) | 2 (5) | 6 (9) | 2 (10) |
| ≥ VGPR | 48 (67) | 25 (64) | 40 (57) | 13 (65) |
| ≥ PR | 69 (96) | 37 (95) | 67 (96) | 19 (95) |
| Response . | Best response to treatment, n (%) . | Responses after 4 and 8 cycles, n (%) . | ||
|---|---|---|---|---|
| All (N = 72) . | At MTD (n = 39) . | At 4 cycles (n = 70) . | At 8 cycles (n = 20)* . | |
| CR + nCR | 28 (39) | 13 (33) | 20 (29) | 7 (35) |
| CR | 21 (29) | 11 (28) | 14 (20) | 5 (25) |
| sCR | 11 (15) | 5 (13) | 1 (1) | 3 (15) |
| nCR | 7 (10) | 2 (5) | 6 (9) | 2 (10) |
| ≥ VGPR | 48 (67) | 25 (64) | 40 (57) | 13 (65) |
| ≥ PR | 69 (96) | 37 (95) | 67 (96) | 19 (95) |
Of 20 patients who completed 8 cycles, 3 subsequently proceeded to ASCT.